Decree n° 2020-1230 of 7 October 2020, on the experimentation of the medical use of cannabis, has been published on Friday 7 October in the French Official Journal. This decree allows the launch of the first experiments on therapeutic cannabis in France.
The text sets out the conditions for implementing experimentation relating to the medical use of cannabis, in particular the conditions for treatment, the number of patients concerned, the procedures for importing, supplying, prescribing and dispensing by hospital and pharmacies, as well as the conditions for informing and monitoring patients and training healthcare professionals.
The French Health Minister will set, by Ministerial Order (to be published) and after receiving the opinion of the general director of the French Agency for the Safety of Medicines and Health Products (ANSM), the characteristics, composition, pharmaceutical form and technical specifications of the cannabis-based medical products.
The experimentation will be authorized for a two-year period starting from the prescription to the first patient or, at the latest, on 31 March 2021, and will involve a maximum of 3,000 patients.
Please note this blog post was written by a Clifford Chance LLP employee. Clifford Chance LLP is the parent company of Clifford Chance Applied Solutions (CCAS). The content within this post does not constitute legal advice.
Décret n° 2020-1230 du 7 octobre 2020 relatif à l'expérimentation de l'usage médical du cannabisNOR : SSAP2021390D